Dalteparin versus enoxaparin for venous thromboembolism prophylaxis in acute spinal cord injury and major orthopedic trauma patients: 'DETECT' trial

Journal of Trauma - Injury, Infection and Critical Care

Volumn 62, Issue 5, 2007, Pages 1075-1081

  Slavik, Richard S ^a,b   Chan, Elfreda ^a   Gorman, Sean K ^a   De Lemos, Jane ^a   Chittock, Dean ^a   Simons, Richard K ^a   Wing, Peter C ^a   Ho, Stephen G F ^a  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b Clinical Services Unit Pharmaceutical Sciences Vancouver Acute Canada   (Canada)

Author keywords

Cost savings; Deep venous thrombosis; Low molecular weight heparin; Pulmonary embolism; Venous thromboembolism prophylaxis

Indexed keywords

DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CHEMOPROPHYLAXIS; COHORT ANALYSIS; CONTROLLED STUDY; COST CONTROL; CRITICALLY ILL PATIENT; DEEP VEIN THROMBOSIS; DEMOGRAPHY; DISEASE SEVERITY; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; ECCHYMOSIS; EPISTAXIS; FEMALE; FEMUR FRACTURE; HEMATOMA; HEMATURIA; HEMOGLOBIN BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; INTENSIVE CARE UNIT; LEG FRACTURE; MAJOR CLINICAL STUDY; MALE; ORTHOPEDICS; OUTCOME ASSESSMENT; PELVIS FRACTURE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SPINAL CORD INJURY; SURGICAL MORTALITY; TERTIARY HEALTH CARE; THROMBOEMBOLISM; TRAUMATOLOGY; VENOUS THROMBOEMBOLISM;

ADULT; COHORT STUDIES; DALTEPARIN; DRUG ADMINISTRATION SCHEDULE; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; FRACTURES, BONE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PULMONARY EMBOLISM; RETROSPECTIVE STUDIES; SPINAL CORD INJURIES; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 34248379151     PISSN: 00225282     EISSN: 15298809     Source Type: Journal    
DOI: 10.1097/TA.0b013e31804fa177     Document Type: Article

References (17)

1. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: Seventh ACCP consensus conference on antithrombotic therapy. Chest. 2004;126:338S-400S.
2. Rogers FB, Cipolle MD, Velmahos G, et al. Practice management guidelines for the prevention of venous thromboembolism in trauma patients: the EAST practice management guidelines work group. J Trauma. 2002;53:142-164.
3. Consortium for Spinal Cord Medicine. Prevention of Thromboembolism in Spinal Cord Injury: Clinical Practice Guideline 2nd Edition. September 1999. Available at http://www.pva.org/cgi-bin/pvastore/products.cgi?id=1. Accessed June 1, 2006.
4. Geerts WH, Code KI, Jay RM, et al. A prospective study of venous thromboembolism after major trauma. N Engl J Med. 1994; 331:1601-1606.
5. Attia J, Ray JG, Cook DJ, et al. Deep vein thrombosis and its prevention in critically ill adults. Arch Intern Med. 2001;161: 1268-1279.
6. Shojania KG, Duncan BW, McDonald KM, et al. Making health care safer: a critical analysis of patient safety practices. Evidence Report/Technology Assessment No. 43 (Prepared by the University of California at San Francisco-Stanford Evidence-based Practice Center under Contract No. 290-97-0013). Rockville, MD: Agency for Healthcare Research and Quality, July 2001; 332-346; AHRQ Publication No. 01-E058. Available at www.ahrq.gov/clinic/ ptsafety/. Accessed November 1, 2006.
7. Berwick DM, Calkins DR, McCannon CJ, et al. The 100,000 lives campaign: setting a goal and a deadline for improving health care quality. JAMA. 2006;295:324-327.
8. Geerts WH, Jay RM, Code KI, et al. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med. 1996; 335:701-707.
9. Spinal Cord Injury Thromboprophylaxis Investigators. Prevention of venous thromboembolism in the acute treatment phase after SCI: a randomized multicenter trial comparing low-dose heparin plus intermittent pneumatic compression with enoxaparin. J Trauma. 2003;54:1116-1126.
10. Smith W, Moore E, Morgan S, et al. Prevention of venous thromboembolism (VTE) in multisystem trauma patients using a single day dose of low molecular weight heparin. Available at http://www.aast.org/02abstracts/02absPoster_081. html. Accessed November 1, 2006.
11. Chiou-Tan FY, Garza H, Chan KT, et al. Comparison of dalteparin and enoxaparin for deep venous thrombosis prophylaxis in patients with spinal cord injury. Am J Phys Med Rehabil. 2003;82:678-685.
12. Mayr AJ, Dunser M, Jochberger S, et al. Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin. Thromb Res. 2002;105:201-204.
13. Priglinger U, Karth D, Geppert A, et al. Prophylacitc anticoagulation with enoxaparin: is the subcutaneous route appropriate in the critically-ill? Crit Care Med. 2003;1405-1409.
14. Dorffler-Melly J, de Jonge E, de Pont AC, et al. Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet. 2002;359:849-850.
15. DeBernardo RL, Perkins RB, Littell RD, et al. Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy. Obstet Gynecol. 2005;105:1006-1011.
16. Abu-Hajir M, Mazzeo AJ. The pharmacology of antithrombotic and antiplatelet agents. Anest Clin North Am. 1999;17:749-786.
17. Schiff RL, Kahn SR, Shrier I, et al. Identifying orthopedic patients at high risk for venous thromboembolism despite thromboprophylaxis. Chest. 2005;128:3364-3371.